XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 38,084 $ 65,064
Short-term marketable securities (amortized cost of $204,757 and $281,122, respectively) 205,245 281,337
Accounts receivable, net 40,814 37,969
Inventory 11,955 14,448
Prepaid expenses and other current assets 12,247 11,370
Total current assets 308,345 410,188
Long-term assets    
Property and equipment, net 51,314 68,227
Operating lease right-of-use assets 46,530 52,096
Long-term marketable securities (amortized cost of $23,857) 23,866  
Restricted cash 2,978 2,932
Intangible assets, net 3,853 5,128
Goodwill 118,972 118,972
Other assets 2,648 3,591
Total assets 558,506 661,134
Current liabilities    
Accounts payable 7,351 7,719
Accrued liabilities 6,062 8,597
Accrued compensation and benefits 12,337 13,685
Current portion of operating lease liabilities 10,021 9,384
Current portion of deferred revenue 51,856 48,630
Total current liabilities 87,627 88,015
Long-term liabilities    
Operating lease liabilities, less current portion 81,804 89,388
Deferred revenue, less current portion 32,781 44,793
Revenue interest liability, net 132,700 130,660
Other long-term liabilities 20  
Total liabilities 334,932 352,856
Commitments and contingencies (Note 9)
Shareholders’ equity    
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023
Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2024 and December 31, 2023; 147,561,586 and 145,082,271 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 14 14
Additional paid-in capital 1,493,394 1,452,502
Accumulated other comprehensive gain 497 215
Accumulated deficit (1,270,132) (1,144,332)
Total Adaptive Biotechnologies Corporation shareholders’ equity 223,773 308,399
Noncontrolling interest (199) (121)
Total shareholders’ equity 223,574 308,278
Total liabilities and shareholders’ equity $ 558,506 $ 661,134